MEDSCI(02415.HK)

Company Encyclopedia
View More
name
MEDSCI
02415.HK
Medsci Healthcare Holdings Limited, an investment holding company, operates as an online professional physician platform service provider in the People’s Republic of China and the United States. The company offers precision omni-channel marketing solutions, including precision detailing, medical content creation, and online survey services; physician platform solutions, such as medical knowledge and clinical study assistance services; and real-world study solutions comprising designing, administration, and execution of digital real-world evidence-based research. It primarily serves pharmaceutical and medical device companies, as well as hospitals and doctors. The company was founded in 2012 and is headquartered in Shanghai, the People’s Republic of China.
59.24 B
02415.HKMarket value -Rank by Market Cap -/-

Financial Score

07/01/2026 Update
C
Health Care TechnologyIndustry
Industry Ranking6/7
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.27%C
    • Profit Margin13.79%B
    • Gross Margin61.86%A
  • Growth ScoreD
    • Revenue YoY-10.65%D
    • Net Profit YoY-12.35%D
    • Total Assets YoY7.06%B
    • Net Assets YoY5.03%B
  • Cash ScoreC
    • Cash Flow Margin725.02%B
    • OCF YoY-10.65%D
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreA
    • Gearing Ratio14.75%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | MEDSCI funds are on the sidelines, will it be a volume-driven surge or a defensive approach?

    MEDSCI (2415.HK) continued to perform poorly yesterday, with the pharmaceutical sector lacking positive stimuli and a bearish sentiment prevailing. Although there was an initial attempt to rise at the beginning of the trading session, it quickly fell back. The overall phenomenon is characterized by converging trading volume and a wait-and-see attitude from major players, with industry news being bleak and the company lacking announcements to provide support, resulting in a severe lack of short-term driving force. The MACD remains in a death cross, indicating a significant weak pattern, and both RSI and the volume-price relationship are not ideal. HKD 1.47 has become a key support zone, with a clear willingness from market leaders to defend it. If it comes under pressure but receives capital replenishment, there may be a partial rebound; conversely, a weak rebound is likely to become a false signal for bullishness. During the trading session, it is essential to closely monitor policy news and capital movements. If there are no significant marginal changes, the risk of high short-term volatility will continue to exist, and investors should focus on risk management

    Technical Forecast·
    HK
    02415
    -0.72%
    Technical Forecast·
    HK
    02415
    -0.72%

    Morning Trend | MEDSCI falls near platform support, will the oversold rebound window come?

    MEDSCI (2415.HK) experienced a round of weak downward movement yesterday, approaching the low point support of the phase platform during the session. The pharmaceutical and health sector has seen a lack of significant news this week, and the industry's defensive attributes have not shown obvious amplification, with short-term funds exhibiting a prominent wait-and-see tendency. There are no highlights in the company's related announcements, and most major players have chosen to observe the situation. Trading volume has shrunk, with slight support at low levels, but there are no signs of a significant rebound. The MACD continues to decline, which technical analysts usually view as a signal of continued weakness. However, once the sector experiences policy catalysts or sudden positive news from leading companies, pharmaceutical stocks often have a rapid recovery capability. Community discussions have shifted focus to whether there can be a time-based stop-loss action in the platform area, and the short-term window may expand with news-related fluctuations. If the platform support is breached, the oversold market may continue to extend, and it is recommended to dynamically track sector rotation sentiment and pay attention to sudden policy catalysts

    Technical Forecast·
    HK
    02415
    -0.72%
    Technical Forecast·
    HK
    02415
    -0.72%

    MedSci Healthcare Says Shanghai Medsci Medtech Awarded Bid For Large-Scale Study

    MedSci Healthcare Holdings Ltd :SHANGHAI MEDSCI MEDTECH AWARDED BID FOR LARGE-SCALE STUDYPROJECT VALUED AT ABOUT RMB21 MILLION

    Reuters·
    HK
    02415
    -0.72%
    Reuters·
    HK
    02415
    -0.72%

    MedSci Secures Major Real-World Study Project in Gout Management

    MedSci Healthcare Holdings Limited (HK:2415) announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has secured a RMB21 million project to conduct a large-scale real-world study on IL-1β monoclonal antibody therapy for gout management. This project highlights MedSci's strategic role in healthcare and its ability to provide digital healthcare solutions, enhancing collaboration with pharmaceutical partners. The company utilizes big data and AI to connect healthcare stakeholders.

    Tip Ranks·
    HK
    02415
    -0.72%
    Tip Ranks·
    HK
    02415
    -0.72%

    MEDSCI's subsidiary wins bid for a large real-world research project "Gout Smart Management Program" from a Chinese pharmaceutical company

    MEDSCI's subsidiary, Shanghai MEDSCI Pharmaceutical Technology Co., Ltd., has won the bid for a large real-world research project titled "Gout Smart Management Program" from a Chinese pharmaceutical company, with a project amount of approximately 21 million yuan. The study will evaluate the efficacy and safety of IL-1β monoclonal antibody treatment in gout patients, combining prospective and retrospective observations. MEDSCI is committed to improving healthcare quality through its internet doctor platform and big data technology

    Zhitong·
    HK
    02415
    -0.72%
    Zhitong·
    HK
    02415
    -0.72%
    © 2026 Longbridge｜Disclaimer